Multitarget drug design strategy in Alzheimer’s disease: focus on cholinergic transmission and amyloid-β aggregation
Background: Alzheimer pathogenesis has been associated with a network of processes working simultaneously and synergistically. Over time, much interest has been focused on cholinergic transmission and its mutual interconnections with other active players of the disease. Besides the cholinesterase ma...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Published: |
Future Science
2017
|
| Subjects: | |
| Online Access: | https://eprints.nottingham.ac.uk/46445/ |
| _version_ | 1848797328087973888 |
|---|---|
| author | Simioni, Elena Bartolini, Manuela Abu, Izuddin Fahmy Blockley, Alix Gotti, Cecilia Bottegoni, Giovanni Caporaso, Roberta Bergamini, Christian Andrisano, Vincenza Cavalli, Andrea Mellor, Ian R. Minarini, Anna |
| author_facet | Simioni, Elena Bartolini, Manuela Abu, Izuddin Fahmy Blockley, Alix Gotti, Cecilia Bottegoni, Giovanni Caporaso, Roberta Bergamini, Christian Andrisano, Vincenza Cavalli, Andrea Mellor, Ian R. Minarini, Anna |
| author_sort | Simioni, Elena |
| building | Nottingham Research Data Repository |
| collection | Online Access |
| description | Background: Alzheimer pathogenesis has been associated with a network of processes working simultaneously and synergistically. Over time, much interest has been focused on cholinergic transmission and its mutual interconnections with other active players of the disease. Besides the cholinesterase mainstay, the multifaceted interplay between nicotinic receptors and amyloid is actually considered to have a central role in neuroprotection. Thus, the multitarget drug-design strategy has emerged as a chance to face the disease network. Results: By exploiting the multitarget approach, the present study provides new molecules able to target the cholinergic pathway, by joining direct nicotinic receptor stimulation to acetylcholinesterase inhibition, and to inhibit Aβ aggregation. Conclusions: These new compounds emerged as a suitable starting point for a further optimization process. |
| first_indexed | 2025-11-14T20:02:07Z |
| format | Article |
| id | nottingham-46445 |
| institution | University of Nottingham Malaysia Campus |
| institution_category | Local University |
| last_indexed | 2025-11-14T20:02:07Z |
| publishDate | 2017 |
| publisher | Future Science |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | nottingham-464452020-05-04T18:51:04Z https://eprints.nottingham.ac.uk/46445/ Multitarget drug design strategy in Alzheimer’s disease: focus on cholinergic transmission and amyloid-β aggregation Simioni, Elena Bartolini, Manuela Abu, Izuddin Fahmy Blockley, Alix Gotti, Cecilia Bottegoni, Giovanni Caporaso, Roberta Bergamini, Christian Andrisano, Vincenza Cavalli, Andrea Mellor, Ian R. Minarini, Anna Background: Alzheimer pathogenesis has been associated with a network of processes working simultaneously and synergistically. Over time, much interest has been focused on cholinergic transmission and its mutual interconnections with other active players of the disease. Besides the cholinesterase mainstay, the multifaceted interplay between nicotinic receptors and amyloid is actually considered to have a central role in neuroprotection. Thus, the multitarget drug-design strategy has emerged as a chance to face the disease network. Results: By exploiting the multitarget approach, the present study provides new molecules able to target the cholinergic pathway, by joining direct nicotinic receptor stimulation to acetylcholinesterase inhibition, and to inhibit Aβ aggregation. Conclusions: These new compounds emerged as a suitable starting point for a further optimization process. Future Science 2017-06-20 Article PeerReviewed Simioni, Elena, Bartolini, Manuela, Abu, Izuddin Fahmy, Blockley, Alix, Gotti, Cecilia, Bottegoni, Giovanni, Caporaso, Roberta, Bergamini, Christian, Andrisano, Vincenza, Cavalli, Andrea, Mellor, Ian R. and Minarini, Anna (2017) Multitarget drug design strategy in Alzheimer’s disease: focus on cholinergic transmission and amyloid-β aggregation. Future Medicinal Chemistry, 9 (10). pp. 953-963. ISSN 1756-8927 Alzheimer’s disease Nicotinic receptors Acetylcholinesterase inhibitors Multitarget compounds Amyloid aggregation. https://www.future-science.com/doi/full/10.4155/fmc-2017-0039 10.4155/fmc-2017-0039 10.4155/fmc-2017-0039 10.4155/fmc-2017-0039 |
| spellingShingle | Alzheimer’s disease Nicotinic receptors Acetylcholinesterase inhibitors Multitarget compounds Amyloid aggregation. Simioni, Elena Bartolini, Manuela Abu, Izuddin Fahmy Blockley, Alix Gotti, Cecilia Bottegoni, Giovanni Caporaso, Roberta Bergamini, Christian Andrisano, Vincenza Cavalli, Andrea Mellor, Ian R. Minarini, Anna Multitarget drug design strategy in Alzheimer’s disease: focus on cholinergic transmission and amyloid-β aggregation |
| title | Multitarget drug design strategy in Alzheimer’s disease: focus on cholinergic transmission and amyloid-β aggregation |
| title_full | Multitarget drug design strategy in Alzheimer’s disease: focus on cholinergic transmission and amyloid-β aggregation |
| title_fullStr | Multitarget drug design strategy in Alzheimer’s disease: focus on cholinergic transmission and amyloid-β aggregation |
| title_full_unstemmed | Multitarget drug design strategy in Alzheimer’s disease: focus on cholinergic transmission and amyloid-β aggregation |
| title_short | Multitarget drug design strategy in Alzheimer’s disease: focus on cholinergic transmission and amyloid-β aggregation |
| title_sort | multitarget drug design strategy in alzheimer’s disease: focus on cholinergic transmission and amyloid-β aggregation |
| topic | Alzheimer’s disease Nicotinic receptors Acetylcholinesterase inhibitors Multitarget compounds Amyloid aggregation. |
| url | https://eprints.nottingham.ac.uk/46445/ https://eprints.nottingham.ac.uk/46445/ https://eprints.nottingham.ac.uk/46445/ |